OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached agreement to launch its own brands
OptiBiotix Health shares: brief investment case overview
OPTI shares have soared in July. Is it too late to get in, or is the company just getting started?
OptiBiotix Health (AIM:OPTI) Launch of GoFigure products on Tmall China
Launch of GoFigure products on Tmall China
OptiBiotix Health (AIM:OPTI) Trading Update
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseanddiabetes, provides the following unaudited trading update ahead of the Group’s half year results for
OptiBiotix Health (AIM:OPTI) ProBiotix Health – Appointment of CEO
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc
AstraZeneca’s Chronic kidney disease Drug Forxiga approved by European Commission
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC). It is now available for chronic kidney disease (CKD), in adults with or without type-2 diabetes (T2D), in the
OptiBiotix Health (OPTI.L) Extension of territories for Seed Health’s DS-01
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended
OptiBiotix Health (OPTI.L) Trading and commercial update
OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes,provides the following unaudited preliminary revenue figures for the first six months ended 30 June
Olav Hellebo, CEO of ReNeuron Group plc (RENE.L) Interview.
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop ‘off the shelf’ stem cell treatments, without the need for immunosuppressive drugs. The Company’s
TPI provides its latest research note on OptiBiotix Health plc (OPTI.L).
OptiBiotix Health plc, the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and cardiovascular health, is now in a pivotal position.
OptiBiotix Health (OPTI.L) Head of Quality & Operations appointment
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces the appointment of Aneta Zlotkowska as Head of Quality & Operations.